Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers
Regulatory go-ahead marks latest boost for drugmaker’s blockbuster anti-obesity franchise
Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s
State-backed insurance programmes would fund drugs for obese patients without separate health conditions
The misses are largely down to inventory issues, rather than weaker demand
US group revises down upper end of full-year revenue estimates
And valuing the weight-loss drug manufacturers
A big market narrative with an eerie absence of sceptics
CBO analysis says savings from other health benefits would not offset expense of weight-loss jabs
The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’
Drugmaker’s CEO sees chance to widen use of anti-obesity medications for ‘health maintenance’
US telehealth groups including Hims & Hers and Ro could find new revenue streams under threat
US group races to overcome production bottleneck to meet demand for anti-obesity medicine Zepbound
The first in an FT series looking at the new energy behind the fight for cancer cures
The Swiss company had the first option on a drug that could now become a leading anti-obesity treatment
Shares soar as ‘strong performance’ of Mounjaro and Zepbound medicines underpin jump in revenue
Pharma companies are moving up the supply chain to secure radioactive materials for a new form of drugs
Swiss drugmaker unveils promising data for obesity drug
New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments
Independent experts conclude unanimously that the experimental treatment is effective
US drugmaker races to scale up ingredient production to meet demand for Mounjaro and Zepbound jabs
Shares of world’s most valuable pharmaceuticals group reapproach record highs
Study results could encourage US Medicare system and private insurers to cover tirzepatide treatments
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
